Canton, Mass., United States: Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients. […]
Seattle, United States: Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the generation of the world’s largest single cell dataset to date, totaling 100 million cells. This impressive milestone was achieved in just one month using Parse Biosciences’ GigaLab and done in partnership […]
Osaka, Japan & Cambridge, Mass., United States: − Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis − Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau − Transaction […]
Stayble Therapeutics AB (“Stayble” or the “Company”) announces positive results from the Company’s clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additionally, STA363-treated patients showed a statistically significant reduction in disc volume compared to placebo-treated patients. The study met its […]
Neogap Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy. Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials. […]
